PMLT21052 / APEC1621A / MullenResearch Question:
Does the drug larotrectinib treat patients with solid tumors, non-Hodgkin lymphoma
or histiocytic disorders?
Basic Study Information
Purpose:Location: University of Rochester
This phase II Pediatric MATCH trial studies how well larotrectinib works in treating
patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK
fusions that may have spread from where it first started to nearby tissue, lymph nodes,
or distant parts of the body (advanced) and have come back (relapased) or does not
respond to treatment (refractory). Larotrectinib may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Thank you for contacting us. People like you are helping URMC make our community and
world a healthier place. We sincerely appreciate your effort. A member of our research
team will be in touch with you.
Trial Not Found
The study you are looking for is not active at this time.
Return to Search